Lipicard (TRICOR)160MG – 100 tablet

>10%: Hepatic: Increased serum transaminases (?3 x ULN: 5% to 13%)

1% to 10%:

Cardiovascular: Pulmonary embolism (?5%), thrombophlebitis (?5%)

Central nervous system: Dizziness (?3%), pain (?3%)

Dermatologic: Skin rash (1%), urticaria (1%)

Gastrointestinal: Abdominal pain (5%), diarrhea (?3%), dyspepsia (?3%), constipation (2%)

Hepatic: Abnormal hepatic function tests (8%), increased serum alanine aminotransferase (3%), increased serum aspartate aminotransferase (3%)

Neuromuscular & skeletal: Arthralgia (?3%), limb pain (?3%), myalgia (?3%), increased creatine phosphokinase in blood specimen (3%)

Respiratory: Nasopharyngitis (?3%), sinusitis (?3%), upper respiratory tract infection (?3%), rhinitis (2%)

<1%, postmarketing, and/or case reports: Acute renal failure, agranulocytosis, anaphylaxis, anemia, angioedema, asthenia, cholestatic hepatitis, chronic active hepatitis, decreased HDL cholesterol (severe), decreased hematocrit, decreased hemoglobin, decreased white blood cell count, drug reaction with eosinophilia and systemic symptoms, headache, hepatic cirrhosis, hepatitis, hepatocellular hepatitis, hypersensitivity reaction, increased serum creatinine, interstitial pulmonary disease, muscle spasm, myopathy, pancreatitis, renal failure syndrome, rhabdomyolysis, severe dermatological reaction (severe cutaneous adverse reactions [SCAR]), skin photosensitivity, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis